Estimaciones de analistas de Wall Street para Crinetics Pharmaceuticals, Inc. (CRNX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 13 |
| Mantener | 8 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 21 |
| Calificación media (1-5) | 0.62 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.20 | ||
| 2026-08-03 | $-1.14 | $-1.18 | +3.4% |
| 2026-05-07 | $-1.23 | $-1.22 | -0.8% |
| 2026-02-26 | $-1.29 | $-1.37 | +5.8% |
| 2025-11-06 | $-1.38 | $-1.27 | -8.7% |
| 2025-08-07 | $-1.23 | $-1.13 | -8.8% |
| 2025-05-08 | $-1.04 | $-0.99 | -5.1% |
| 2025-02-27 | $-0.88 | $-0.92 | +4.3% |
Ratios de valoración
| Precio / Valor contable | 7.52 |
| EV / EBITDA | -17.68 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $589000 | $2.0M | $2.4M | $1.2M | $71000 | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M |
| Coste de Ventas | $5.1M | $9.2M | $24.5M | $1.1M | $57.0M | 0 | 0 | 0 | 0 | $1.1M |
| Beneficio Bruto | -$4.5M | -$7.2M | -$22.1M | $80000 | -$56.9M | $1.1M | $4.7M | $4.0M | $1.0M | $6.6M |
| I+D | $5.1M | $9.2M | $24.5M | $41.5M | $57.6M | $84.3M | $130.2M | $168.5M | $240.2M | $332.1M |
| Generales y Administrativos | $1.5M | $1.9M | $6.7M | $13.5M | $18.0M | $24.5M | $42.4M | $58.1M | $99.7M | $191.3M |
| Gastos Operativos | $6.0M | $9.1M | $28.7M | $53.8M | $18.0M | $108.8M | $172.6M | $226.6M | $339.9M | $523.4M |
| Beneficio Operativo | -$6.0M | -$9.1M | -$28.7M | -$53.8M | -$75.0M | -$107.7M | -$167.9M | -$222.6M | -$338.9M | -$516.8M |
| EBITDA | -$6.0M | -$9.0M | -$28.2M | -$49.3M | -$74.0M | -$106.7M | -$162.9M | -$213.4M | -$295.6M | -$461.2M |
| Gastos por Intereses | $11000 | $8000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$6.0M | -$9.2M | -$27.1M | -$50.4M | -$73.8M | -$107.6M | -$163.9M | -$214.5M | -$298.4M | -$465.1M |
| Impuestos | $10000 | -$40000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $180000 |
| Beneficio Neto | -$6.0M | -$9.2M | -$27.1M | -$49.5M | -$73.8M | -$107.6M | -$163.9M | -$214.5M | -$298.4M | -$465.3M |
| BPA | $-0.43 | $-0.66 | $-2.23 | $-2.05 | $-2.42 | $-2.80 | $-3.15 | $-3.69 | $-3.69 | $-4.95 |
| BPA Diluido | $-0.43 | $-0.66 | $-2.23 | $-2.05 | $-2.42 | $-2.80 | $-3.15 | $-3.69 | $-3.69 | $-4.95 |
| Acciones en Circulación (Diluidas) | $13.9M | $13.9M | $12.1M | $24.2M | $30.4M | $38.4M | $52.0M | $58.1M | $80.8M | $94.1M |
Precio
| Precio | $84.95 |
| Capitalización | $9.0B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACAD · AKRO · DYN · IMVT · KYMR · NAMS · PRAX
Explorar sector: Healthcare · Biotechnology
Más secciones de CRNX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones